Background Cerebral palsy (CP) is the most common cause of physical disabilities in
children in high‐income countries. Spasticity is the most common motor disturbance in CP …

Background Botulinum toxin (BTX) injection alone is not sufficient to treat spasticity in
children, notably those with cerebral palsy; thus, there is an emerging trend for adjunct …

Cerebral palsy (CP) is heterogeneous in etiology and manifestations, making research into
relevant therapies difficult and limiting the generalizability of the results. We report here on …

Objective: Botulinum toxin (BoNT-A) is widely used in combined treatment for spastic
cerebral palsy, but its added value preceding comprehensive rehabilitation for motor …

In 1997, lanbotulinumtoxinA (LAN) was introduced in China. It is now available in Asia, Latin
America and Eastern Europe under various brand names including Hengli®, Lantox® …

Background: Botulinum toxin type A (BTX-A) is a neuromuscular blocking agent. BTX-A
inhibits acetylcholine release, causes neuromuscular transmission impairment, and …

This study aimed to evaluate efficacy of group (GRP) versus individual (IND) physiotherapy
rehabilitation following lower limb intramuscular injections of Botulinum Toxin-Type A (BoNT …

Objective: To describe the current state of the art in the therapeutic administration of
botulinum toxin with indications, efficacy, and safety profile for children and adolescents with …

Neuromusculoskeletal rehabilitation of cerebral palsy using SEMLARASS Page 204 Chapter
6 Neuromusculoskeletal Rehabilitation of Cerebral Palsy Using SEMLARASS Deepak Sharan …

Cerebral palsy (CP) is due to an insult to the developing brain and is the most common
cause of motor deficiency in young children and usually leads to muscle spasticity …